WntResearch recently announced that the Spanish authorities have approved the revised study plan for the phase II study NeoFox with the drug candidate Foxy-5 in colon cancer. The company has introduced new endpoints on the primary tumour already at the patients' surgery, which enables significantly earlier data readout and thus cost and time savings.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
0.067 SEK | -.--% | -.--% | -27.17% |
May. 03 | WntResearch AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Feb. 29 | WntResearch AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 | CI |
1st Jan change | Capi. | |
---|---|---|
-27.17% | 5.37M | |
+9.15% | 105B | |
-1.08% | 104B | |
+5.79% | 22.94B | |
-11.55% | 22.34B | |
-7.01% | 19.25B | |
-37.08% | 17.08B | |
-9.91% | 16.96B | |
+7.55% | 14.16B | |
+40.04% | 12.63B |
- Stock Market
- Equities
- WNT Stock
- News WntResearch AB
- WntResearch AB Announces New Study Plan Approves for Wnt Research's Phase II Study